Valeant Pharmaceuticals International, Inc. VRX today announced that its subsidiary, Biovail Laboratories International SRL, has entered into an agreement to license the Canadian rights to ACZONE Gel 5%, a topical formulation of dapsone used in the treatment of acne vulgaris, from Allergan.
Allergan will receive from BLS a CA$500,000 upfront payment to be followed by subsequent additional payments based on net sales.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in